Axsome Therapeutics, Inc.
0HKF.L
London Stock Exchange249.26
USD
-2.58
- -
Axsome Therapeutics, Inc.
0HKF.L
(London Stock Exchange)
Recent
price
249.26
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders with limited treatment options. The company offers Auvelity (dextromethorphan-bupropion), an oral NMDA receptor antagonist indicated for major depressive disorder in adults; Sunosi (solriamfetol), a dopamine/norepinephrine reuptake inhibitor for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea; and pipeline candidates including AXS-12 (reboxetine) for narcolepsy, AXS-14 (esreboxetine) for fibromyalgia, and others targeting migraine, Alzheimer's agitation, and attention deficit hyperactivity disorder. Founded in 2012 and headquartered in New York, New York, Axsome Therapeutics primarily operates in the United States, targeting patients and healthcare providers in the CNS therapeutics market through its commercial infrastructure. Recent developments include the 2021 acquisition of Sunosi from Jazz Pharmaceuticals, enabling revenue diversification and commercial-stage transition; FDA approval and 2023 launch of Auvelity, driving significant net product sales growth to $270.6 million year-to-date through Q3 2024; and in 2025, acquisition of global rights to AZD7325, a subtype-selective GABAA receptor positive allosteric modulator from AstraZeneca via Baergic Bio, Inc., a subsidiary of Avenue Therapeutics, for potential epilepsy treatment with Phase 2 activities planned for 2026. These strategic moves expand Axsome's CNS portfolio amid robust revenue increases, including 63% growth in Q3 2025 led by Auvelity and Symbravo.